1. Scrip
  2. >>Business
  3. >>Deals

Celgene's $1.1bn Impact Buy Is First Of More Deals To Come In 2018 And Beyond

 
• By Mandy Jackson

Celgene believes it's acquiring a $1bn drug, not a me-too JAK inhibitor in its purchase of Impact Biomedicines for $1.1bn up front. Investors appeared skeptical of fedratinib's potential, but the company said at the J.P. Morgan meeting that it will execute more deals to build out its pipeline.

Two businessmen shaking hands during a meeting in the office, success, dealing, greeting & business partner concepts - soft light.

Celgene Corp. has high hopes for its latest acquisition, Impact Biomedicines, whose fedratinib is envisioned as one of multiple blockbuster drugs in the company's mostly-partnered late-stage pipeline – and the purchase for $1.1bn up front is likely just one of multiple deals to come in 2018.

"We remain committed to business development," Celgene CEO Mark Alles said during the Q&A session after his presentation at the J.P. Morgan Healthcare Conference that kicked off on Jan. 8 and ends on Jan

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

More from Business

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.